Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.57 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.57 |
| ▸ | CA3 | P07451 | 3/20 | 0.57 |
| ▸ | CA4 | P22748 | 3/20 | 0.57 |
| ▸ | CA6 | P23280 | 3/20 | 0.57 |
| ▸ | CA5A | P35218 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 3/20 | 0.57 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17645102 | 1.00 | CA2 (0.57) | CA2CA1CA12CA9CA14 | |
| SCHEMBL5501401 | 0.82 | CA2 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL515001 | 0.82 | CA1 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL2307427 | 0.79 | CA1 (0.53) | CA2CA1CA12CA9CA14 | |
| SCHEMBL1416363 | 0.79 | KMT2A (0.68) | CA2CA1CA5AACHEMMP1 | |
| SCHEMBL29382330 | 0.78 | CA2 (0.57) | CA2CA1CA12CA9CA14 | |
| SCHEMBL1498131 | 0.77 | CA2 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL17295223 | 0.77 | CA2 (0.60) | CA2CA1CA12CA9CA14 | |
| SCHEMBL11855965 | 0.77 | CA2 (0.67) | CA2CA1CA12CA9CA14 | |
| SCHEMBL3158508 | 0.77 | CA2 (0.67) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112390697-B | Synthesis method of N-arylselenium/thioethyl sulfoxide imine | 成都理工大学 | 2023-03-10 | — | — | CN | claimed |
| CN-112390697-A | Synthesis method of N-arylselenium/thioethyl sulfoxide imine | 成都理工大学 | 2021-02-23 | — | — | CN | claimed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| WO-2025073057-A1 | METHODS FOR PREPARING SULFILIMINES AND SULFOXIMINES FROM THIOETHERS USING O-(DIPHENYLPHOSPHINYL)HYDROXYL AMINE (DPPH), AND AMATOXIN ANALOGS PREPARED FROM SUCH METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024238574-A1 | CDK INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-112390697-B | Synthesis method of N-arylselenium/thioethyl sulfoxide imine | 成都理工大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-115667264-A | Novel imidazo-pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20060217353-A1 | 24-sulfoximine vitamin D3 compounds | CYTOCHROMA INC. (CA) | 2006-09-28 | — | — | US | disclosed |
| US-7101865-B2 | 24-sulfoximine vitamin D3 compounds | CYTOCHROMA INC. (CA) | 2006-09-05 | — | — | US | disclosed |
| EP-1673352-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CDK AND/OR VEGF INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005037800-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES FOR USE AS CDK AND/OR VEGF INHIBITORS, THE PRODUCTION THEREOF AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | WO | disclosed |
| EP-1511725-A1 | 24-SULFOXIMINE VITAMIN D sb 3 /sb COMPOUNDS | Johns Hopkins University (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040038949-A1 | 24-sulfoximine vitamin D3 compounds | JOHNS HOPKINS UNIVERSITY | 2004-02-26 | — | — | US | disclosed |
| WO-2003106411-A1 | 24-SULFOXIMINE VITAMIN D3 COMPOUNDS | JOHNS HOPKINS UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-4556413-A | POSTEMERGENCE AND PREEMERGENCE HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0109575-A2 | Benzoic-acid derivatives, process and means for its production | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038949-A1 | 24-sulfoximine vitamin D3 compounds | CYP24A1, CYP2R1, CYP27B1 | CA2 2871/4885CA1 3379/4885CA12 2566/4885 |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | CA2 3761/4885CA1 4878/4885CA12 4564/4885 |
| US-20060217353-A1 | 24-sulfoximine vitamin D3 compounds | CYP24A1, CYP2R1, CYP27B1 | CA2 3149/4885CA1 3533/4885CA12 2864/4885 |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CDK2, CCNI, CCNK | CA2 2006/4885CA1 3820/4885CA12 4658/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | CA2 4746/4885CA1 4870/4885CA12 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.